Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990924 | 1.00 | MDM2 (0.79) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL11713368 | 0.88 | MDM2 (1.00) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL3355858 | 0.86 | MDM2 (0.88) | MDM2CYP1A2CTNNB1KMT2ACPA3 | |
| SCHEMBL7037701 | 0.86 | MDM2 (0.88) | MDM2CYP1A2CTNNB1KMT2ACPA3 | |
| SCHEMBL7164412 | 0.83 | MDM2 (0.81) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL6990929 | 0.83 | MDM2 (0.81) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL6990936 | 0.83 | MDM2 (0.81) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL2138695 | 0.81 | MDM2 (0.79) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL9242408 | 0.81 | MDM2 (0.79) | MDM2CYP1A2CTRB1CTNNB1KMT2A | |
| SCHEMBL7274785 | 0.79 | MDM2 (0.53) | MDM2CYP1A2CTRB1CPA3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544980-B2 | For treating neoplasms, atherosclerosis, and chronic inflammatory diseases | AVENTIS PHARMACEUTICALS INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020095035-A1 | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase | WARSHAWSKY ALAN M (US) | 2002-07-18 | — | — | US | disclosed |
| EP-1150957-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000040564-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-0750631-B1 | NOVEL MERCAPTOACETYLAMIDO 1,3,4,5-TETRAHYDRO-BENZO(C)AZEPIN-3-ONE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMA INC (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5880119-A | Mercaptoacetylamino 1,3,4,5-tetrahydro-benzo(C)azepin-2-one disulfide derivatives useful as inhibitors of enkephalinase and ACE | MERRELL PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5731306-A | Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo c!azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace | AVENTISUB II INC. | 1998-03-24 | — | — | US | disclosed |
| EP-0750631-A1 | NOVEL MERCAPTOACETYLAMIDO 1,3,4,5-TETRAHYDRO-BENZO(C)AZEPIN-3-ONE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMACEUTICALS INC. (US) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995021854-A1 | NOVEL MERCAPTOACETYLAMIDO 1,3,4,5-TETRAHYDRO-BENZO[C]AZEPIN-3-ONE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095035-A1 | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase | MMP17, MMP26, MMP16 | MDM2 2532/4885CYP1A2 648/4885CTRB1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.